Edwards Lifesciences (NYSE:EW) Price Target Raised to $110.00

Edwards Lifesciences (NYSE:EW) had its price objective increased by equities researchers at Citigroup from $101.00 to $110.00 in a report issued on Wednesday, MarketBeat reports. The firm currently has a “buy” rating on the medical research company’s stock. Citigroup’s price objective indicates a potential upside of 16.05% from the stock’s previous close.

Other research analysts have also recently issued research reports about the stock. Evercore reiterated an “outperform” rating and set a $100.00 price target on shares of Edwards Lifesciences in a report on Monday. Royal Bank Of Canada restated an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a report on Tuesday, June 16th. Canaccord Genuity Group set a $85.00 price objective on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. Truist Financial set a $90.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th. Finally, Wolfe Research raised Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price on the stock in a report on Wednesday, April 1st. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $97.09.

Edwards Lifesciences Price Performance

EW stock opened at $94.79 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The firm has a market capitalization of $54.58 billion, a P/E ratio of 50.42, a P/E/G ratio of 2.39 and a beta of 0.86. The business’s 50-day moving average is $86.13 and its two-hundred day moving average is $83.71. Edwards Lifesciences has a 1 year low of $72.30 and a 1 year high of $96.29.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. During the same period in the previous year, the company posted $0.64 earnings per share. The business’s revenue for the quarter was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Analysts anticipate that Edwards Lifesciences will post 3 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares in the company, valued at $1,319,950.72. This trade represents a 3.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the sale, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at approximately $3,177,507.96. This trade represents a 24.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 57,958 shares of company stock worth $4,839,284 over the last 90 days. 0.31% of the stock is owned by corporate insiders.

Institutional Trading of Edwards Lifesciences

A number of hedge funds and other institutional investors have recently made changes to their positions in EW. Brighton Jones LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $266,000. NewEdge Advisors LLC raised its position in Edwards Lifesciences by 8.1% in the 2nd quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock valued at $2,787,000 after purchasing an additional 2,665 shares during the last quarter. Sei Investments Co. raised its position in Edwards Lifesciences by 16.7% in the 2nd quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock valued at $32,285,000 after purchasing an additional 58,988 shares during the last quarter. Squarepoint Ops LLC boosted its stake in Edwards Lifesciences by 277.7% during the 2nd quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock worth $5,417,000 after purchasing an additional 50,924 shares during the period. Finally, Treasurer of the State of North Carolina boosted its stake in Edwards Lifesciences by 0.4% during the 2nd quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock worth $21,028,000 after purchasing an additional 1,065 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.